Impact of Incomplete Coronary Revascularization on Late Ischemic and Bleeding Events after Transcatheter Aortic Valve Replacement.
baseline SYNTAX score
bleeding
residual SYNTAX score
transcatheter aortic valve replacement
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
16 Jul 2020
16 Jul 2020
Historique:
received:
16
05
2020
revised:
16
06
2020
accepted:
14
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
The impact of coronary artery disease (CAD) and revascularization by percutaneous coronary intervention (PCI) on prognosis in patients undergoing transcatheter aortic valve replacement (TAVR) remain debated. A dismal prognosis in patients undergoing PCI has been associated with elevated baseline SYNTAX score (bSS) and residual SYNTAX score (rSS). The objective was to investigate whether the degree of bSS and rSS impacted ischemic and bleeding events after TAVR. bSS and rSS were calculated in 311 patients admitted for TAVR. The primary outcome was the occurrence of major adverse cardiac events (MACE), a composite endpoint of myocardial infarction, stroke, cardiovascular death, or rehospitalization for heart failure. The occurrence of late major/life-threatening bleeding complications (MLBCs) and each primary endpoint individually were the secondary endpoints. bSS > 22 was associated with higher occurrence of MACE ( Incomplete coronary revascularization and CAD burden did not impact overall and cardiac mortality but constitute predictors of late MLBCs in TAVR patients.
Sections du résumé
BACKGROUND
BACKGROUND
The impact of coronary artery disease (CAD) and revascularization by percutaneous coronary intervention (PCI) on prognosis in patients undergoing transcatheter aortic valve replacement (TAVR) remain debated. A dismal prognosis in patients undergoing PCI has been associated with elevated baseline SYNTAX score (bSS) and residual SYNTAX score (rSS). The objective was to investigate whether the degree of bSS and rSS impacted ischemic and bleeding events after TAVR.
METHODS
METHODS
bSS and rSS were calculated in 311 patients admitted for TAVR. The primary outcome was the occurrence of major adverse cardiac events (MACE), a composite endpoint of myocardial infarction, stroke, cardiovascular death, or rehospitalization for heart failure. The occurrence of late major/life-threatening bleeding complications (MLBCs) and each primary endpoint individually were the secondary endpoints.
RESULTS
RESULTS
bSS > 22 was associated with higher occurrence of MACE (
CONCLUSIONS
CONCLUSIONS
Incomplete coronary revascularization and CAD burden did not impact overall and cardiac mortality but constitute predictors of late MLBCs in TAVR patients.
Identifiants
pubmed: 32708771
pii: jcm9072267
doi: 10.3390/jcm9072267
pmc: PMC7408638
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur Heart J. 2014 Oct 1;35(37):2530-40
pubmed: 24682843
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
Eur Heart J. 2014 Jun 21;35(24):1588-98
pubmed: 24022003
J Am Coll Cardiol. 2014 Mar 25;63(11):1100-9
pubmed: 24291283
Can J Cardiol. 2015 Jun;31(6):738-43
pubmed: 25935884
J Am Coll Cardiol. 2018 Oct 30;72(18):2139-2148
pubmed: 30360823
Lifetime Data Anal. 2004 Mar;10(1):29-49
pubmed: 15130049
JACC Cardiovasc Interv. 2013 Aug;6(8):867-75
pubmed: 23871511
N Engl J Med. 2016 Jul 28;375(4):335-44
pubmed: 27464202
Catheter Cardiovasc Interv. 2010 Aug 1;76(2):165-73
pubmed: 20665855
Eur J Cardiothorac Surg. 2017 Oct 1;52(4):616-664
pubmed: 29156023
EuroIntervention. 2005 Aug;1(2):219-27
pubmed: 19758907
JACC Cardiovasc Interv. 2015 Apr 27;8(5):692-700
pubmed: 25946442
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
Circulation. 2019 Sep 3;:
pubmed: 31476897
JACC Cardiovasc Interv. 2017 Jul 24;10(14):1436-1446
pubmed: 28728657
Lancet. 2015 Jun 20;385(9986):2477-84
pubmed: 25788234
Eur Heart J. 1994 Jul;15(7):865-70
pubmed: 7925504
Circulation. 1993 Nov;88(5 Pt 2):II17-23
pubmed: 8222150
J Am Coll Cardiol. 2012 Oct 9;60(15):1438-54
pubmed: 23036636
J Am Coll Cardiol. 1997 Mar 1;29(3):630-4
pubmed: 9060903
J Heart Valve Dis. 1993 Jul;2(4):430-9
pubmed: 8269146
J Thorac Cardiovasc Surg. 1990 Sep;100(3):327-37
pubmed: 2391969
N Engl J Med. 2003 Jul 24;349(4):343-9
pubmed: 12878741
J Am Coll Cardiol. 2013 Feb 26;61(8):837-48
pubmed: 23428216
N Engl J Med. 2012 May 3;366(18):1705-15
pubmed: 22551129
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Am Heart J. 2014 Jul;168(1):68-75.e2
pubmed: 24952862
Int J Cardiol. 2019 Feb 15;277:60-65
pubmed: 30293666
Thromb Haemost. 2018 May;118(5):893-905
pubmed: 29590670
J Am Coll Cardiol. 2012 Jun 19;59(25):2317-26
pubmed: 22503058
Int J Cardiol. 2013 Aug 10;167(3):943-50
pubmed: 22459391
J Invasive Cardiol. 2015 Apr;27(4):203-11
pubmed: 25840404
Catheter Cardiovasc Interv. 2016 Nov;88(5):740-747
pubmed: 26833916
Circulation. 2013 Jul 9;128(2):141-51
pubmed: 23766350
JAMA Cardiol. 2016 May 1;1(2):198-204
pubmed: 27437891
J Am Coll Cardiol. 2013 Jul 2;62(1):1-10
pubmed: 23644089
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Int J Cardiol. 2017 Oct 15;245:215-221
pubmed: 28789844
J Am Coll Cardiol. 1987 Jul;10(1):66-72
pubmed: 3496372